Smith & Nephew: KDJ Golden Cross, Bullish Marubozu on 15min Chart
ByAinvest
Tuesday, Jul 22, 2025 2:50 pm ET1min read
EHAB--
Smith & Nephew operates in approximately 100 countries and generated annual sales of $5.8 billion in 2024. The company's portfolio includes orthopaedics, sports medicine and ENT, and advanced wound management products, and it is a constituent of the FTSE 100 index.
In addition to the financial results, market analysts are closely watching Smith & Nephew's technical indicators. Recent chart analysis suggests a significant shift in the stock's momentum. As of July 22, 2025, at 14:45, the 15-minute chart triggered a KDJ Golden Cross and a Bullish Marubozu, indicating a potential upside in the stock price. These technical indicators suggest that buyers are dominating the market, signaling continued bullish momentum [2].
Investors should stay tuned for the upcoming financial results and the conference call to gain insights into Smith & Nephew's performance and future prospects. The company's strong market presence and diversified product portfolio make it a key player in the medical technology sector.
References:
[1] https://www.investing.com/news/sec-filings/smith--nephew-schedules-release-of-second-quarter-and-halfyear-2025-results-93CH-4144135
[2] [Provided writing topic]
SNN--
Smith & Nephew's 15-minute chart has recently triggered a KDJ Golden Cross and a Bullish Marubozu at 07/22/2025 14:45. This indicates a shift in the momentum of the stock price towards the upside, with potential for further growth. The dominance of buyers in the market suggests that bullish momentum is likely to continue.
Smith & Nephew plc (LSE: SN, NYSE: SNN), a leading medical technology company, has scheduled the release of its second-quarter and first-half 2025 financial results for the period ended June 28, 2025. The company will publish these results on Tuesday, August 5, 2025, at 7:00 a.m. BST (2:00 a.m. EDT), and will also hold a conference call for financial analysts at 8:30 a.m. BST (3:30 a.m. EDT) on the same day [1].Smith & Nephew operates in approximately 100 countries and generated annual sales of $5.8 billion in 2024. The company's portfolio includes orthopaedics, sports medicine and ENT, and advanced wound management products, and it is a constituent of the FTSE 100 index.
In addition to the financial results, market analysts are closely watching Smith & Nephew's technical indicators. Recent chart analysis suggests a significant shift in the stock's momentum. As of July 22, 2025, at 14:45, the 15-minute chart triggered a KDJ Golden Cross and a Bullish Marubozu, indicating a potential upside in the stock price. These technical indicators suggest that buyers are dominating the market, signaling continued bullish momentum [2].
Investors should stay tuned for the upcoming financial results and the conference call to gain insights into Smith & Nephew's performance and future prospects. The company's strong market presence and diversified product portfolio make it a key player in the medical technology sector.
References:
[1] https://www.investing.com/news/sec-filings/smith--nephew-schedules-release-of-second-quarter-and-halfyear-2025-results-93CH-4144135
[2] [Provided writing topic]
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet